Leaflet: information for the user
Zaldiar 37.5 mg/325 mg film-coated tablets
Tramadol hydrochloride/Paracetamol
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What Zaldiar is and what it is used for
2. What you need to know before you start taking Zaldiar
3. How to take Zaldiar
4. Possible side effects
5. Storage of Zaldiar
6. Contents of the pack and additional information
Zaldiar is a combination of two analgesics, tramadol and paracetamol, which act together to relieve pain.
Zaldiar is indicated for symptomatic treatment of moderate to intense pain whenever your doctor believes that the combination of tramadol and paracetamol is necessary.
Zaldiar should only be used by adults and adolescents over 12 years old.
Warnings and precautions
Consult your doctor before starting to take Zaldiar, if
Tolerance, dependence and addiction
This medicine contains tramadol, which is an opioid medication. Repeated use of opioids can make the medication less effective (the body becomes accustomed to it, known as pharmacological tolerance). Repeated use of Zaldiar can also cause dependence, abuse and addiction, which could lead to a potentially fatal overdose. The risk of these adverse effects may be higher with a higher dose and longer use.
Dependence or addiction can cause a feeling of lack of control over the amount of medication you should use or the frequency with which you should use it.
The risk of dependence or addiction varies from person to person. The risk of becoming dependent or addicted to Zaldiar may be higher if:
- You or any member of your family have abused alcohol or experienced dependence on it, prescription medications or illegal drugs ("addiction").
- You are a smoker.
- You have had any problems with mood (depression, anxiety or personality disorder) or have followed treatment with a psychiatrist for other mental health conditions.
If you observe any of the following symptoms while using Zaldiar, it could be a sign of dependence or addiction:
– You need to use the medication for a longer time than indicated by your doctor.
– You need to use a higher dose than recommended.
– You are using the medication for reasons other than those prescribed, for example, "to feel calm" or "to help you sleep".
– You have made repeated and unsuccessful attempts to stop using the medication or control its use.
– You feel unwell when you stop using the medication, and you feel better once you take it again ("withdrawal symptoms").
If you notice any of these signs, consult your doctor to determine the best course of treatment for you, when it is appropriate to stop taking the medication and how to do it safely (see section 3, if you interrupt treatment with Zaldiar).
Sleep-related respiratory disorders
Zaldiar contains an active ingredient that belongs to the group of opioids. Opioids can cause sleep-related respiratory disorders; for example, central sleep apnea (shallow breathing or pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood).
The risk of experiencing central sleep apnea depends on the dose of opioids. Your doctor may consider reducing the total dose of opioids if you experience central sleep apnea.
There is a weak risk that you may experience a serotonin syndrome that can occur after taking tramadol in combination with certain antidepressants or tramadol alone. Consult your doctor immediately if you experience any of the symptoms associated with this serious syndrome (see section 4 "Possible side effects").
Tramadol is metabolized in the liver by an enzyme. Some people have a variation of this enzyme and this can affect each person differently. In some people, it may not be possible to achieve sufficient pain relief, while others may be more likely to experience severe adverse effects. If you notice any of the following adverse effects, stop taking this medication and consult your doctor immediately: slow or shallow breathing, confusion, drowsiness, constricted pupils, general discomfort or vomiting, constipation, loss of appetite.
If you experience or have experienced any of these problems while taking Zaldiar, please inform your doctor. He will decide whether you should continue taking this medication.
Use in children with respiratory problems:
Tramadol should not be used in children with respiratory problems, as the symptoms of tramadol toxicity can worsen in these children.
Inform your doctor if you experience any of the following symptoms while taking Zaldiar:
Extreme fatigue, loss of appetite, severe abdominal pain, nausea, vomiting or low blood pressure. They may be indicative of adrenal insufficiency (low cortisol levels). If you have these symptoms, contact your doctor, who will decide if you need to take hormone supplements.
Taking Zaldiar with other medicines
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medication.
Important: This medicine contains paracetamol and tramadol. Inform your doctorif you are taking any other medication that contains paracetamol or tramadol, so as not to exceed the maximum daily dose.
Zaldiarshould not be takenwith monoamine oxidase inhibitors (MAOIs) (see section "Do not take Zaldiar").
Zaldiar should not be used if you are being treated with:
Inform your doctor or pharmacist if you are taking:
The risk of adverse effects increases if you are taking:
The concomitant use of Zaldiar and sedatives such as benzodiazepines or related medications increases the risk of drowsiness, respiratory difficulties (respiratory depression), coma and may be potentially fatal. For this reason, concomitant use should only be considered when other treatment options are not possible. However, if your doctor prescribesyou this medicationwith sedatives, you should limit the dose and duration of concomitant treatment.
Inform your doctor of all sedatives you are taking and follow your doctor's dose recommendation strictly. It may be helpful to inform your friends and family about the signs and symptoms mentioned above. Inform your doctor if you experience any of these symptoms.
The effectiveness of Zaldiar may be altered if you are also taking:
Your doctor will know which medications are safe to use with Zaldiar.
Taking Zaldiar with food and alcohol
Zaldiar may make you feel drowsy. Alcohol can make you feel drowsy, so it is recommended not to take alcohol while taking Zaldiar.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Due to the fact that Zaldiar contains tramadol, it is not recommended to take this medication during pregnancy or breastfeeding. If you become pregnant during treatment with Zaldiar, consult your doctor before taking the next tablet.
Tramadol is excreted in breast milk. For this reason, you should not take Zaldiar more than once during breastfeeding or, if you take Zaldiar more than once, you should stop breastfeeding.
Based on human experience, it is not suggested that tramadol affects male and female fertility. There are no data available on the combination of tramadol and paracetamol in fertility.
Driving and operating machinery
Ask your doctor if you can drive or operate machinery during treatment with Zaldiar. It is essential to observe how this medication affects you before driving or operating machinery. Do not drive or operate machinery if you feel drowsy, dizzy, have blurred vision or double vision, or have difficulty concentrating. Be particularly careful at the start of treatment, after increasing the dose, after changing the formulation, and/or when taking it with other medications.
Zaldiar contains lactose and sodium
This medication contains lactose. If your doctor has told you that you have a intolerance to certain sugars, consult with him before taking this medication.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; that is, it is essentially "sodium-free".
You should take Zaldiar for the shortest time possible.
This medication is not recommended for use in children under 12 years old.
The dose should be adjusted to the intensity of the pain and your individual sensitivity. Normally, the lowest dose possible that produces pain relief should be used.
Unless your doctor prescribes otherwise, the recommended starting dose for adults and adolescents over 12 years old is 2 tablets.
If necessary, you can increase the dose as recommended by your doctor. The shortest interval between doses should be at least 6 hours.
Do not take more than 8 Zaldiar tablets per day.
Do not take Zaldiar more frequently than your doctor has indicated.
Older patients
In elderly patients (over 75 years old), the elimination of tramadol may be slow. If this is your case, your doctor may recommend prolonging the dosing intervals.
Patients with liver or kidney disease/patients on dialysis
If you have a severe liver or kidney disease, treatment with Zaldiar is not recommended. If you have moderate liver or kidney disease, your doctor may prolong the dosing intervals.
Administration form
Zaldiar is presented in the form of tablets for oral administration.
The tablets should be swallowed whole with sufficient liquid. They should not be broken or chewed.
If you estimate that the effect of Zaldiar is too strong (e.g. you feel very drowsy or have difficulty breathing) or too weak (e.g. you do not have adequate pain relief), inform your doctor.
If you take more Zaldiar than you should
If you have taken more Zaldiar than you should, even if you feel well, consult your doctor or pharmacist immediately, as there is a risk of severe liver damage that will only become apparent later.
In case of overdose or accidental ingestion, consult the Toxicological Information Service, phone 91 562 04 20.
If you forget to take Zaldiar
If you forget to take a dose of Zaldiar, it is likely that the pain will recur. Do not take a double dose to compensate for the missed doses, simply continue taking the tablets as usual.
If you interrupt treatment with Zaldiar
You should not stop taking this medication suddenly unless your doctor tells you to. If you want to stop taking your medication, talk to your doctor first, especially if you have been taking it for a long time. Your doctor will inform you when and how to discontinue it, which can be done by gradually reducing the dose to reduce the likelihood of unnecessary adverse effects (withdrawal symptoms).
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Very common: may affect more than 1 in 10 people;
Common: may affect 1 in 10 people;
Uncommon: may affect 1 in 100 people;
Rare: may affect 1 in 1,000 people;
Frequency not known:
The following adverse effects recognized have been reported by people who have taken medications containing only tramadol or only paracetamol. However, if you experience any of these symptoms while taking Zaldiar, please tell your doctor:
In rare cases, using a medication like tramadol can make you dependent on it, making it difficult to stop taking it.
In rare instances, people who have been taking tramadol for some time may feel unwell if they stop treatment abruptly. They may feel agitated, anxious, nervous or shaky. They may be hyperactive, have difficulty sleeping and experience gastrointestinal and intestinal disorders. Very few people may also experience panic attacks, hallucinations, unusual perceptions such as itching, tingling and numbness, and ear noises (tinnitus). If you experience any of these symptoms after stopping treatment with Zaldiar, please consult your doctor.
Frequency not known: hiccups.
In exceptional cases, blood tests may reveal certain abnormalities, such as low platelet count, which may result in nasal or gum bleeding.
In very rare cases, severe skin reactions with paracetamol have been reported.
There have been reports of rare cases of respiratory depression with tramadol.
Reporting of adverse effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date appearing on the packaging after CAD. The expiration date is the last day of the month indicated. This medication does not require special storage conditions.
Medications should not be disposed of through drains or trash. Dispose of packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Each film-coated tablet contains 37.5 mg of tramadol hydrochloride and 325 mg of paracetamol.
Core of the tablet: powdered cellulose, pregelatinized cornstarch, sodium starch glycolate (type A), cornstarch, magnesium stearate.
Coating film: hypromellose, lactose monohydrate, titanium dioxide (E171), macrogol 6000, yellow iron oxide (E172), propylene glycol (E1520), talc.
Appearance of the product and contents of the package
Zaldiar film-coated tablets are pale yellow tablets marked with the manufacturer's logo on one side and “T5” on the other.
Zaldiar film-coated tablets are packaged in blisters.
They are presented in packs of 2, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 tablets.
Only some pack sizes may be marketed.
Zaldiar film-coated tablets are presented in packs of 2x1, 10x1, 20x1, 30x1, 40x1, 50x1, 60x1, 70x1, 80x1, 90x1 or 100x1 tablets in a pre-cut single-dose blister.
Only some pack sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Grünenthal Pharma, S.A.
Doctor Zamenhof, 36 – 28027 Madrid, Spain
Responsible for manufacturing:
Grünenthal GmbH
Zieglerstrasse 6–D- 52078 Aachen, Germany
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany | Zaldiar 37.5 mg/325 mg Filmtabletten |
Austria | Zaldiar 37.5 mg/325 mg Filmtabletten |
Belgium | Zaldiar 37.5 mg/325 mg, coated tablets / filmomhulde tabletten |
Pontalsic37.5 mg/325 mg, coated tablets / filmomhulde tabletten | |
Slovenia | Zaldiar 37.5 mg/325 mg film-coated tablets |
Spain | Zaldiar 37.5 mg/325 mg film-coated tablets |
Pontalsic 37.5 mg/325 mg film-coated tablets | |
France | Zaldiar 37.5 mg/325 mg, coated tablet |
Ixprim 37.5 mg/325 mg, coated tablet | |
Greece | ZALDIAR |
Netherlands | Zaldiar 37.5 mg/325 mg, filmomhulde tabletten |
Hungary | Zaldiar 37.5 mg/325 mg filmtabletta |
Ireland | Ixprim 37.5 mg/325 mg, film-coated tablets |
Luxembourg | Zaldiar 37.5 mg/325 mg, coated tablets |
Portugal | Zaldiar 37.5 mg/325 mg film-coated tablets |
United Kingdom | Tramacet 37.5 mg/325 mg, film-coated tablets |
Last review date of this leaflet: December 2024
For detailed and updated information on this medicine, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.